Buy Eli Lilly While The Market Hesitates And Let Time Make You Dominate

Invictus Origin, a new high-alpha investment management firm founded by Oliver Rodzianko and launching in May 2025, aims to deliver consistent outperformance via its Nasdaq High-Alpha Black Swan Portfolio, which strategically allocates approximately 20% to cash for robust downside protection. Rodzianko, an experienced macro-focused analyst specializing in technology, semiconductors, and AI, emphasizes fundamental valuation and long-term cycles, positioning the firm for resilient performance and disciplined capital stewardship.

Analysis

Invictus Origin, a new investment management firm launching in May 2025, is introducing a high-alpha strategy focused on outperforming the Nasdaq-100. Its key differentiator is the flagship Nasdaq High-Alpha Black Swan Portfolio, which maintains an approximate 20% strategic cash reserve intended to mitigate downside risk and provide flexibility during market dislocations. The firm's founder, Oliver Rodzianko, brings a stated expertise in macro analysis with a focus on technology, semiconductors, AI, and energy, emphasizing fundamental valuation and long-term cycles. While the article's tone is highly optimistic about the firm's potential, its market impact score is exceptionally low at 0.1, indicating this announcement is not a market-moving event. The disclosure of the founder's long positions in Eli Lilly (LLY), Nvidia (NVDA), and Advanced Micro Devices (AMD) provides the most concrete, albeit limited, insight into his current sector convictions.

Key Decisions for Investors

• Given the firm is pre-launch, investors should monitor the performance of the Nasdaq High-Alpha Black Swan Portfolio after May 2025 to verify its ability to deliver on its stated goals of alpha generation and capital preservation.
• Track the founder's public research on platforms such as Seeking Alpha for early indicators of his investment theses, particularly within his specialized sectors like AI and semiconductors.
• The disclosed long positions in NVDA, AMD, and LLY should be noted as a data point reflecting conviction in high-growth technology and healthcare, but should not be acted upon without independent due diligence as the article provides no specific supporting analysis.